Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Myung Soo | - |
dc.contributor.author | Chung, Ho Seok | - |
dc.contributor.author | Hwang, Eu Chang | - |
dc.contributor.author | Jung, Seung Il | - |
dc.contributor.author | Kwon, Dong Deuk | - |
dc.contributor.author | Hwang, Jun Eul | - |
dc.contributor.author | Bae, Woo Kyun | - |
dc.contributor.author | Park, Jae Young | - |
dc.contributor.author | Jeong, Chang Wook | - |
dc.contributor.author | Kwak, Cheol | - |
dc.contributor.author | Song, Cheryn | - |
dc.contributor.author | Seo, Seong Il | - |
dc.contributor.author | Byun, Seok-Soo | - |
dc.contributor.author | Hong, Sung-Hoo | - |
dc.contributor.author | Chung, Jinsoo | - |
dc.date.accessioned | 2021-09-02T01:40:13Z | - |
dc.date.available | 2021-09-02T01:40:13Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-12-17 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/70888 | - |
dc.description.abstract | Background: To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice. Methods: Data of 554 patients with mRCC who received SU or PZ at eight institutions between 2012 and 2016 were retrospectively reviewed. Based on the targeted therapy, the patients were divided into SU (n = 293) or PZ (n = 261) groups, and the clinicopathological variables and survival rates of the two groups were compared. A multivariable Cox proportional hazard model was used to determine the prognostic factors for OS. Results: The median follow-up was 16.4 months (interquartile range, 8.3-31.3). Patients in the PZ group were older, and no significant difference was observed in the performance status (PS) between the two groups. In the SU group, the dose reduction rate was higher and the incidence of grade 3 toxicity was more frequent. The objective response rates were comparable between the two groups (SU, 32.1% vs. PZ, 36.4%). OS did not differ significantly between the two groups (SU, 36.5 months vs. PZ, 40.2 months; log-rank, P= 0.955). Body mass index, Eastern Cooperative Oncology Group PS > 2, synchronous metastasis, poor Heng risk criteria, and liver and bone metastases were associated with a shorter OS. Conclusion: Our real-world data of Korean patients with mRCC suggested that SU and PZ had similar efficacies as first-line therapy for mRCC. However, PZ was better tolerated than SU in Korean patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | PROGNOSTIC-FACTORS | - |
dc.subject | SURVIVAL | - |
dc.subject | OUTCOMES | - |
dc.subject | BONE | - |
dc.subject | TRIAL | - |
dc.title | Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Jae Young | - |
dc.identifier.doi | 10.3346/jkms.2018.33.e325 | - |
dc.identifier.scopusid | 2-s2.0-85058602379 | - |
dc.identifier.wosid | 000453388900002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.33, no.51 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 33 | - |
dc.citation.number | 51 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002413442 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | BONE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Renal Cell Carcinoma | - |
dc.subject.keywordAuthor | Neoplasm Metastasis | - |
dc.subject.keywordAuthor | Sunitinib | - |
dc.subject.keywordAuthor | Pazopanib | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.